Ru-Lan Hsieh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ru-Lan Hsieh has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Wen-Chung Lee
13 shared publications- Wen-Chung Lee
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University , Taipei 100
13 shared publications Wei-Cheng Liao
Department of Physical Medicine and Rehabilitation, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei 110, Taiwan
5 shared publicationsHorng-Sheng Shiue
Department of Chinese Medicine, Chang Gung University College of Medicine
3 shared publicationsMin-Tzu Lo
3 shared publicationsMing-I Lin
Department of Pediatrics, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
3 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (8) , e47771
Effects of arch support insoles on the standing balance of community-dwelling older adults with mild cognitive impairment
People with mild cognitive impairment (MCI) exhibit subtle but measurable cognitive deficits and a decline in balance. This study explored the effects of arch support insoles on standing balance in community-dwelling older adults with MCI. This was a quasi-experimental study with a single-group pre- and post-test design. Fifteen older adults with MCI were enrolled in the study. Postural stability, fall risk, and limits of stability tests, as well as the modified Clinical Test of Sensory Interaction on Balance, were conducted using the Biodex balance system SD before and after an 8-week intervention with arch support insoles. After the intervention, the fall risk index (1.27 ± 0.50 vs 0.87 ± 0.33, P = .006) decreased significantly. Some medium-to-large effect sizes were noted in the postural stability index and foam surface with eyes open testing condition of the modified Clinical Test of Sensory Interaction on Balance. The use of arch support insoles may enhance standing balance in older adults with MCI; it may contribute to fall prevention in this population. Further well-designed controlled trials are warranted to strengthen causal inferences.
- 20 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (8) , e47771
Open AccessEffects of arch support insoles on the standing balance of community-dwelling older adults with mild cognitive impairment
People with mild cognitive impairment (MCI) exhibit subtle but measurable cognitive deficits and a decline in balance. This study explored the effects of arch support insoles on standing balance in community-dwelling older adults with MCI. This was a quasi-experimental study with a single-group pre- and post-test design. Fifteen older adults with MCI were enrolled in the study. Postural stability, fall risk, and limits of stability tests, as well as the modified Clinical Test of Sensory Interaction on Balance, were conducted using the Biodex balance system SD before and after an 8-week intervention with arch support insoles. After the intervention, the fall risk index (1.27 ± 0.50 vs 0.87 ± 0.33, P = .006) decreased significantly. Some medium-to-large effect sizes were noted in the postural stability index and foam surface with eyes open testing condition of the modified Clinical Test of Sensory Interaction on Balance. The use of arch support insoles may enhance standing balance in older adults with MCI; it may contribute to fall prevention in this population. Further well-designed controlled trials are warranted to strengthen causal inferences.
- Open Access
- 1 January 2025
- Published by Taiwan Academy of Physical Medicine and Rehabilitation in Rehabilitation Practice and Science
- Vol. 2025 (1) , 8
Multidisciplinary Approach to Managing Hypotonia and Developmental Delays Due to a Novel GTPBP3 Mutation
Introduction: Hypotonia in early life is often challenging to diagnose due to its diverse etiologies, with genetic disorders accounting for about one-third of cases. A precise diagnosis using a comprehensive, multidisciplinary approach is crucial for determining prognosis, guiding treatment, and providing genetic counseling. Case Presentation: We report the first case in Taiwan involving compound heterozygous mutations in the GTPBP3 gene. A 13-month-old girl presented with developmental delays and hypotonia despite normal prenatal screenings and a year of rehabilitation therapy. Next-generation sequencing revealed two novel mutations: c.785A>C (p.Gln262Pro), a missense mutation in Exon 5, and c.1175_1181dup (p.Ser395GlufsTer4), a frameshift duplication in Exon 7. Both variants were classified as likely pathogenic based on the American College of Medical Genetics and Genomics (ACMG) guidelines. Sanger sequencing confirmed a trans inheritance pattern, with the father carrying the c.785A>C mutation and the mother carrying the c.1175_1181dup mutation. The asymptomatic sibling carried only the c.785A>C variant, supporting an autosomal recessive model. The patient received individualized care from a multidisciplinary team, including a pediatric physiatrist, physical, occupational, and speech therapists, along with support from a social worker. By 46 months, the patient demonstrated significant progress in both motor and language skills. Conclusion: This case underscores the importance of early genetic testing in infants with unexplained hypotonia. Identifying compound heterozygous GTPBP3 mutations allowed for precise diagnosis and guided effective, personalized interventions, highlighting the value of integrating genetic evaluation into clinical management for rare developmental disorders.
- 1 January 2025
- Published by Taiwan Academy of Physical Medicine and Rehabilitation in Rehabilitation Practice and Science
- Vol. 2025 (1) , 8
Open AccessMultidisciplinary Approach to Managing Hypotonia and Developmental Delays Due to a Novel GTPBP3 Mutation
Introduction: Hypotonia in early life is often challenging to diagnose due to its diverse etiologies, with genetic disorders accounting for about one-third of cases. A precise diagnosis using a comprehensive, multidisciplinary approach is crucial for determining prognosis, guiding treatment, and providing genetic counseling. Case Presentation: We report the first case in Taiwan involving compound heterozygous mutations in the GTPBP3 gene. A 13-month-old girl presented with developmental delays and hypotonia despite normal prenatal screenings and a year of rehabilitation therapy. Next-generation sequencing revealed two novel mutations: c.785A>C (p.Gln262Pro), a missense mutation in Exon 5, and c.1175_1181dup (p.Ser395GlufsTer4), a frameshift duplication in Exon 7. Both variants were classified as likely pathogenic based on the American College of Medical Genetics and Genomics (ACMG) guidelines. Sanger sequencing confirmed a trans inheritance pattern, with the father carrying the c.785A>C mutation and the mother carrying the c.1175_1181dup mutation. The asymptomatic sibling carried only the c.785A>C variant, supporting an autosomal recessive model. The patient received individualized care from a multidisciplinary team, including a pediatric physiatrist, physical, occupational, and speech therapists, along with support from a social worker. By 46 months, the patient demonstrated significant progress in both motor and language skills. Conclusion: This case underscores the importance of early genetic testing in infants with unexplained hypotonia. Identifying compound heterozygous GTPBP3 mutations allowed for precise diagnosis and guided effective, personalized interventions, highlighting the value of integrating genetic evaluation into clinical management for rare developmental disorders.
- 22 December 2024
- Published by Elsevier in Musculoskeletal Science and Practice
- Vol. 75, 103248
Short-term effects of exergaming on patients with chronic low back pain: A single-blind randomized controlled trial
- 22 December 2024
- Published by Elsevier in Musculoskeletal Science and Practice
- Vol. 75, 103248
Short-term effects of exergaming on patients with chronic low back pain: A single-blind randomized controlled trial
- Open Access
- 7 November 2023
- Published by Springer Nature in Research Square
The effects of Customized Arch Support Insoles for Children with developmental delays: A Prospective, Single-blind, Randomized Controlled Study
Using arch support insoles for children with motor developmental delays requires further evidence. This study aims to evaluate the short-term effects of customized arch support insoles on these children, adopting the International Classification of Functioning, Disability, and Health (ICF) framework for our analysis. Participants were randomly assigned to either the treatment group, which received customized insoles, or the control group (waitlisted), which did not receive any insoles during a 12-week intervention. The primary outcome focused on physical health, measured using the Pediatric Outcome Data Collection Instrument-Parent (PODCI). Secondary outcomes included balance (measured via the Berg Balance Scale), physical functional performance (10-meter walking test, stair climbing test, and Timed Up and Go test), and health-related quality of life (assessed using the Pediatric Quality of Life Inventory, PedsQL). A significant improvement was observed in the regular walking speed of the treatment group compared to the control group (0.13 m/s vs. 0.013 m/s, P < .001), and nearly met the criteria for minimal clinically important difference. However, no significant differences were noted between the groups regarding changes in scores from the PODCI, Berg Balance Scale, Timed Up and Go test, most physical functional performance, and PedsQL. Conclusion: The 12-week use of customized arch support insoles in children with motor developmental delays showed a marginal improvement in regular walking speed, and the improvement did not extend to physical health status, most physical functional performance, or health-related quality of life. Thus, we do not recommend arch support insoles for children with motor developmental delays. Trial registration ClinicalTrials.gov: NCT03191006 (Registered June 22, 2017).
- 7 November 2023
- Published by Springer Nature in Research Square
Open AccessThe effects of Customized Arch Support Insoles for Children with developmental delays: A Prospective, Single-blind, Randomized Controlled Study
Using arch support insoles for children with motor developmental delays requires further evidence. This study aims to evaluate the short-term effects of customized arch support insoles on these children, adopting the International Classification of Functioning, Disability, and Health (ICF) framework for our analysis. Participants were randomly assigned to either the treatment group, which received customized insoles, or the control group (waitlisted), which did not receive any insoles during a 12-week intervention. The primary outcome focused on physical health, measured using the Pediatric Outcome Data Collection Instrument-Parent (PODCI). Secondary outcomes included balance (measured via the Berg Balance Scale), physical functional performance (10-meter walking test, stair climbing test, and Timed Up and Go test), and health-related quality of life (assessed using the Pediatric Quality of Life Inventory, PedsQL). A significant improvement was observed in the regular walking speed of the treatment group compared to the control group (0.13 m/s vs. 0.013 m/s, P < .001), and nearly met the criteria for minimal clinically important difference. However, no significant differences were noted between the groups regarding changes in scores from the PODCI, Berg Balance Scale, Timed Up and Go test, most physical functional performance, and PedsQL. Conclusion: The 12-week use of customized arch support insoles in children with motor developmental delays showed a marginal improvement in regular walking speed, and the improvement did not extend to physical health status, most physical functional performance, or health-related quality of life. Thus, we do not recommend arch support insoles for children with motor developmental delays. Trial registration ClinicalTrials.gov: NCT03191006 (Registered June 22, 2017).
- Retracted
- 5 September 2023
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
No Difference Between One-shot Co-injection of Corticosteroids and Hyaluronic Acid in a Three-injection Regimen for Knee Osteoarthritis: A Randomized, Double-blind Trial [RETRACTED]
Background Although many guidelines now recommend against hyaluronic acid (HA) injections alone for the nonoperative management of knee osteoarthritis (OA), prior studies have disagreed about whether adding an intra-articular corticosteroid to HA results in sufficient benefit to justify the potential dose-dependent and time-dependent chondrotoxicity of corticosteroids. Questions/purposes (1) Do patients with knee OA treated with low-dose intra-articular corticosteroids and HA administered under ultrasound guidance have more favorable patient-reported knee OA–related outcomes from 1 to 26 weeks after treatment than those treated with ultrasound-guided HA injections alone? (2) Do patients treated with a corticosteroid co-injection exhibit more favorable physical functional performance than those treated with injections of HA alone? Methods We conducted a randomized, double-blind trial at a small medical center in urban Taipei, Taiwan. We considered those who fulfilled the clinical and radiographic criteria for knee OA, defined by the American College of Rheumatology as a Kellgren-Lawrence grade 2 or 3, as potentially eligible. We excluded those who had a previous knee fracture or surgery and those who had received intra-articular knee injections of HA or corticosteroids within 6 months of the trial. Based on these criteria, 78 patients were eligible, and 76 agreed to be randomized to the co-injection or HA-only groups through block randomization. The groups had 38 patients each; all participants who completed the study follow-up were analyzed in the groups to which they were randomized and treated. There was no crossover. The patients in the co-injection group were treated with a one-shot co-injection of HA with corticosteroids (Hyruan Plus: molecular weight, 3000 kDa, 10 mg/mL HA, 2 mL with triamcinolone acetonide 10 mg/dL, 1 mL) in the first week followed by two injections of HA (10 mg/mL, 2 mL) at a 1-week interval. The patients in the HA-only group received three HA injections (Hyruan Plus: molecular weight, 3000 kDa, 10 mg/mL HA, 2 mL) administered at a 1-week interval. A senior physiatrist performed ultrasound-guided knee injections using the lateral suprapatellar approach. The physiatrist, participants, and outcome assessor were all blinded to the injection contents. No differences were observed between the two groups regarding primary demographic data, baseline WOMAC and Knee Injury and Osteoarthritis Outcome Score (KOOS) scores, and physical functional performance. Three participants experienced localized swelling after the injections, and all symptoms improved after a few days of localized ice pack application. A total of 3.9% of patients (three of 76) had adverse events (mainly localized swelling of the knee, with or without accompanying pain), with no between-group differences in the frequency of adverse events. No severe side effects were reported during or after the injections. The patient-reported outcomes were the WOMAC and KOOS scores. The objective outcome was physical function performance (speed for 10-meter regular and fastest walking, and time for stair-climbing and chair-rising). The primary outcome timepoint was 6 months postinjection. A sample size of 34 participants was required in each group, based on a difference in WOMAC scores of 58 points, a significance level of 0.05, and a power of 0.8. Results We found no difference in improvement from baseline between the two groups regarding patient-reported outcomes at any follow-up timepoint, from 1 week after injection to 6 months. At 6 months post-treatment, compared with baseline, there were no between-group differences in improvement between the co-injection group and the HA-only group in terms of WOMAC pain scores (mean difference 1 [95% CI -2 to 3]; p = 0.62), stiffness (mean difference -11 [95% CI -13 to -9]; p < 0.001), and physical function (mean difference -4 [95% CI -5 to -3]; p < 0.001) and KOOS scores for pain, other symptoms, activities of daily living, sports and recreation, and quality of life. Except for chair-rising time at 6 months, which may have represented spurious significance because of the number of comparisons, compared with baseline, we found no differences in improvement between the two groups regarding the regular and fastest walking speed and stair ascent and descent time. Conclusion We found that a single co-injection of corticosteroids along with HA did not confer any additional benefit regarding patient-reported outcomes or physical function compared with a three-injection regimen of HA. Therefore, we do not recommend a one-shot co-injection of corticosteroids alongside the three-injection regimen of HA for patients with knee OA, and because prior research found HA to be ineffective, HA should not be used with or without corticosteroids for patients with knee OA. Level of Evidence Level I, therapeutic study.
- 5 September 2023
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
RetractedNo Difference Between One-shot Co-injection of Corticosteroids and Hyaluronic Acid in a Three-injection Regimen for Knee Osteoarthritis: A Randomized, Double-blind Trial [RETRACTED]
Background Although many guidelines now recommend against hyaluronic acid (HA) injections alone for the nonoperative management of knee osteoarthritis (OA), prior studies have disagreed about whether adding an intra-articular corticosteroid to HA results in sufficient benefit to justify the potential dose-dependent and time-dependent chondrotoxicity of corticosteroids. Questions/purposes (1) Do patients with knee OA treated with low-dose intra-articular corticosteroids and HA administered under ultrasound guidance have more favorable patient-reported knee OA–related outcomes from 1 to 26 weeks after treatment than those treated with ultrasound-guided HA injections alone? (2) Do patients treated with a corticosteroid co-injection exhibit more favorable physical functional performance than those treated with injections of HA alone? Methods We conducted a randomized, double-blind trial at a small medical center in urban Taipei, Taiwan. We considered those who fulfilled the clinical and radiographic criteria for knee OA, defined by the American College of Rheumatology as a Kellgren-Lawrence grade 2 or 3, as potentially eligible. We excluded those who had a previous knee fracture or surgery and those who had received intra-articular knee injections of HA or corticosteroids within 6 months of the trial. Based on these criteria, 78 patients were eligible, and 76 agreed to be randomized to the co-injection or HA-only groups through block randomization. The groups had 38 patients each; all participants who completed the study follow-up were analyzed in the groups to which they were randomized and treated. There was no crossover. The patients in the co-injection group were treated with a one-shot co-injection of HA with corticosteroids (Hyruan Plus: molecular weight, 3000 kDa, 10 mg/mL HA, 2 mL with triamcinolone acetonide 10 mg/dL, 1 mL) in the first week followed by two injections of HA (10 mg/mL, 2 mL) at a 1-week interval. The patients in the HA-only group received three HA injections (Hyruan Plus: molecular weight, 3000 kDa, 10 mg/mL HA, 2 mL) administered at a 1-week interval. A senior physiatrist performed ultrasound-guided knee injections using the lateral suprapatellar approach. The physiatrist, participants, and outcome assessor were all blinded to the injection contents. No differences were observed between the two groups regarding primary demographic data, baseline WOMAC and Knee Injury and Osteoarthritis Outcome Score (KOOS) scores, and physical functional performance. Three participants experienced localized swelling after the injections, and all symptoms improved after a few days of localized ice pack application. A total of 3.9% of patients (three of 76) had adverse events (mainly localized swelling of the knee, with or without accompanying pain), with no between-group differences in the frequency of adverse events. No severe side effects were reported during or after the injections. The patient-reported outcomes were the WOMAC and KOOS scores. The objective outcome was physical function performance (speed for 10-meter regular and fastest walking, and time for stair-climbing and chair-rising). The primary outcome timepoint was 6 months postinjection. A sample size of 34 participants was required in each group, based on a difference in WOMAC scores of 58 points, a significance level of 0.05, and a power of 0.8. Results We found no difference in improvement from baseline between the two groups regarding patient-reported outcomes at any follow-up timepoint, from 1 week after injection to 6 months. At 6 months post-treatment, compared with baseline, there were no between-group differences in improvement between the co-injection group and the HA-only group in terms of WOMAC pain scores (mean difference 1 [95% CI -2 to 3]; p = 0.62), stiffness (mean difference -11 [95% CI -13 to -9]; p < 0.001), and physical function (mean difference -4 [95% CI -5 to -3]; p < 0.001) and KOOS scores for pain, other symptoms, activities of daily living, sports and recreation, and quality of life. Except for chair-rising time at 6 months, which may have represented spurious significance because of the number of comparisons, compared with baseline, we found no differences in improvement between the two groups regarding the regular and fastest walking speed and stair ascent and descent time. Conclusion We found that a single co-injection of corticosteroids along with HA did not confer any additional benefit regarding patient-reported outcomes or physical function compared with a three-injection regimen of HA. Therefore, we do not recommend a one-shot co-injection of corticosteroids alongside the three-injection regimen of HA for patients with knee OA, and because prior research found HA to be ineffective, HA should not be used with or without corticosteroids for patients with knee OA. Level of Evidence Level I, therapeutic study.
- 2 March 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 143, 26-33
Feasibility of Family-Centered Workshops for Children Aged 18-36 Months with Language Developmental Delay
- 2 March 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 143, 26-33
Feasibility of Family-Centered Workshops for Children Aged 18-36 Months with Language Developmental Delay
- Open Access
- 15 February 2023
- Published by Springer Nature in Pediatric Research
- Vol. 94 (2) , 707-714
Short-term multidisciplinary family-centered workshop for preschool children with global developmental delays
Background Children with developmental delays have a great impact on their families. Educating families on how to interact with their children is an important task. Therefore, we assessed the short-term effectiveness of the workshop for children with global developmental delays. Methods In total, 101 children aged 18–36 months with global developmental delays, all with language delay along with other developmental delays, and their parents participated in six 2-h family-centered workshop sessions for six weeks. Measures were taken before and after the workshop, including the Mandarin-Chinese Communicative Developmental Inventory, Peabody Developmental Motor Scales, Emotional Competency Rating Scales, Pediatric Outcomes Data Collection Instrument, Pediatric Evaluation of Disability Inventory, Pediatric Daily Occupation Scale, Pediatric Quality of Life Inventory (PedsQL), Caregiver Strain Index, and PedsQL-Family Impact Module. Results Significant improvements with a small or intermediate effect size in emotions, upper extremity and physical functioning and global functioning, daily occupation performance in sensorimotor, communication, cognitive autonomy, and psychosocial domains, and parental quality of life and family impact were noted with high workshop satisfaction. Conclusion Short-term family-centered workshop is effective for children with global developmental delays. However, due to the lack of follow-up after the intervention, it should be careful in inferring the developmental gain effect. Impact The effectiveness of short-term family-centered workshops on children with global developmental delays remains uncertain. Short-term family-centered workshops improved the children’s emotions, physical functional performance, and occupational performance in daily life. The short-term family-centered workshop is practical and effective for children with global developmental delays. Further long-term, large-scale, prospective, randomized trials are warranted to confirm these results. Clinical trial registration ClinicalTrials.gov ID: NCT05418933
- 15 February 2023
- Published by Springer Nature in Pediatric Research
- Vol. 94 (2) , 707-714
Open AccessShort-term multidisciplinary family-centered workshop for preschool children with global developmental delays
Background Children with developmental delays have a great impact on their families. Educating families on how to interact with their children is an important task. Therefore, we assessed the short-term effectiveness of the workshop for children with global developmental delays. Methods In total, 101 children aged 18–36 months with global developmental delays, all with language delay along with other developmental delays, and their parents participated in six 2-h family-centered workshop sessions for six weeks. Measures were taken before and after the workshop, including the Mandarin-Chinese Communicative Developmental Inventory, Peabody Developmental Motor Scales, Emotional Competency Rating Scales, Pediatric Outcomes Data Collection Instrument, Pediatric Evaluation of Disability Inventory, Pediatric Daily Occupation Scale, Pediatric Quality of Life Inventory (PedsQL), Caregiver Strain Index, and PedsQL-Family Impact Module. Results Significant improvements with a small or intermediate effect size in emotions, upper extremity and physical functioning and global functioning, daily occupation performance in sensorimotor, communication, cognitive autonomy, and psychosocial domains, and parental quality of life and family impact were noted with high workshop satisfaction. Conclusion Short-term family-centered workshop is effective for children with global developmental delays. However, due to the lack of follow-up after the intervention, it should be careful in inferring the developmental gain effect. Impact The effectiveness of short-term family-centered workshops on children with global developmental delays remains uncertain. Short-term family-centered workshops improved the children’s emotions, physical functional performance, and occupational performance in daily life. The short-term family-centered workshop is practical and effective for children with global developmental delays. Further long-term, large-scale, prospective, randomized trials are warranted to confirm these results. Clinical trial registration ClinicalTrials.gov ID: NCT05418933
- 1 May 2022
- Published by Elsevier in The American Journal of Medicine
- Vol. 135 (5) , 641-649
Effects of Repeated Co-Injections of Corticosteroids and Hyaluronic Acid on Knee Osteoarthritis: A Prospective, Double-Blind Randomized Controlled Trial
- 1 May 2022
- Published by Elsevier in The American Journal of Medicine
- Vol. 135 (5) , 641-649
Effects of Repeated Co-Injections of Corticosteroids and Hyaluronic Acid on Knee Osteoarthritis: A Prospective, Double-Blind Randomized Controlled Trial
- 16 April 2022
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 103 (8) , 1505-1514
Effects of Intra-articular Coinjections of Hyaluronic Acid and Hypertonic Dextrose on Knee Osteoarthritis: A Prospective, Randomized, Double-Blind Trial
- 16 April 2022
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 103 (8) , 1505-1514
Effects of Intra-articular Coinjections of Hyaluronic Acid and Hypertonic Dextrose on Knee Osteoarthritis: A Prospective, Randomized, Double-Blind Trial